MoonLake Immunotherapeutics says it’s cleared the bar in a Phase II trial of its IL-17A and IL-17F inhibitor in hidradenitis suppurativa.
In its 234-patient MIRA study, MoonLake said it succeeded on the primary goal — more patients on its investigational med sonelokimab achieved at least a 75% reduction from baseline in total abscess and inflammatory nodule count than those on placebo. People with HS experience recurring nodules and abscesses in the armpits, groin and buttocks, and sinus tracts. It leads to pain and sometimes stigmatization.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters